Do commercial weight loss programmes actually work?

Against standard primary care, yes, and this is the strongest head to head evidence any consumer diet product on this site has. Referral to a commercial programme produced minus 5.06 kg against minus 2.25 kg on standard care at twelve months, and a 52-week referral produced minus 6.76 kg against minus 3.26 kg on brief advice. An independent systematic review of 45 studies put the twelve-month advantage at at least 2.6 percent of body weight for the group programme and at least 4.9 percent for the prepared-meal one.

Who paid for those trials?

Mostly the company being tested. The two largest European trials were funded by Weight Watchers International, in both cases through UK Medical Research Council mechanisms. That is disclosed in the papers and it belongs in any honest reading of them. It also cuts both ways: the industry-funded trials published high attrition and a cost per kilogram, and the systematic review that declares no funding source reached a favourable conclusion about the same programme.

Does the weight stay off?

Partly, for as long as anyone has looked, which is two years. The two-year comparison against self-help finished at minus 2.9 against minus 0.2 kg, down from minus 4.3 at one year. The prepared-meal trial finished at 7.4 kg down at 24 months. The very low calorie medical programmes are the exception in both directions: 15 to 25 percent loss in completers, and a high probability of regaining half or more within one to two years.

Is one programme better than another?

Not on the direct comparison. Four commercial programmes run head to head for six months all beat control and did not differ significantly from each other, averaging 5.9 kg lost. In a network meta-analysis of 48 trials the differences between named diets were minimal while behavioural support accounted for 3.23 kg at six months. The structure appears to be the active ingredient, not the brand.

Two randomised trials tested it. In prediabetes, twelve months produced 5.5 percent weight loss against 0.2 percent on a national counselling programme, with better HbA1c and HDL. In type 2 diabetes, HbA1c moved minus 0.32 against plus 0.16 percentage points, 24 against 14 percent reached HbA1c below 7.0, and 26 against 12 percent reduced their diabetes medications. That last figure is why anyone on insulin or a sulfonylurea should tell their prescriber before joining.

Macronutrient-defined8 human studies cited

Commercial weight loss programmes

Written by Aaron CuhaReviewed Sep 2026

Also called: WW, Weight Watchers, Jenny Craig, Nutrisystem, Slimming World

The best-evidenced consumer diet product on this site, for an unglamorous reason: these are the only patterns whose owners paid for head to head randomised trials. Referral from primary care roughly doubled twelve-month weight loss against standard care, and most of the funding came from the company being tested.

What it actually is

A paid behavioural programme rather than a diet. In the trials the active components were a simplified energy accounting system, weekly weigh-ins, group meetings and, in some versions, provided food. The randomised evidence base is narrower than the category suggests: it is dominated by trials of one group programme, now called WW and formerly Weight Watchers, and by the prepared-meal model represented by Jenny Craig, Nutrisystem and the medically supervised very low calorie programmes. Several widely used commercial products, including app-first programmes, have little or no randomised evidence at all.

The mechanism its advocates propose

Not a macronutrient claim. The proposition is behavioural: structure, accountability, a simplified way to count, group reinforcement and a defined food plan raise adherence, and adherence is what produces weight loss. Stated fairly, this is the only popular diet claim covered on this site that does not assert a metabolic advantage over any other diet, and it happens to be the claim the trials support best. The head to head evidence agrees with it in an awkward way: in a network meta-analysis of 48 trials and 7,286 people, the differences between individual named diets were minimal while behavioural support contributed 3.23 kg at six months.

What happened when calories were controlled

Strongest design available: prescribed, self-reported

Participants were told what to eat and reported back. Under-reporting is the norm rather than the exception, so the actual intake in each arm is unknown.

Never, and in this case that is the correct design rather than a weakness. The intervention is a behaviour change programme, so the outcome of interest is what people actually eat when nobody is supervising them. Controlling intake would delete the thing being tested.

Jebb 2011 randomised 772 overweight and obese adults recruited through primary care practices in Australia, Germany and the UK to twelve months of standard care as defined by national guidelines or twelve months of free commercial programme membership. Weight change at twelve months, carrying the last observation forward, was minus 5.06 kg against minus 2.25 kg, an adjusted difference of minus 2.77 kg (95% CI minus 3.50 to minus 2.03). Carrying baseline forward instead gives minus 4.06 against minus 1.77 kg. Among completers only it was minus 6.65 against minus 3.26 kg. Completion was 61 and 54 percent. Funded by Weight Watchers International through a grant to the UK Medical Research Council.
WRAP, Ahern 2017, is the dose trial. 1,267 adults from 23 English practices randomised 2:5:5 to brief advice and self-help materials, twelve weeks of the programme, or 52 weeks of it. One-year weight change was minus 3.26, minus 4.75 and minus 6.76 kg. The behavioural programme beat brief advice by minus 2.71 kg (95% CI minus 3.86 to minus 1.55, p < 0.0001) and 52 weeks beat twelve by minus 2.14 kg (minus 3.05 to minus 1.22, p < 0.0001), with differences still significant at two years. Follow-up was 65 percent at one year and 68 percent at two. Incremental cost-effectiveness over two years was 91 pounds per kg lost for the twelve-week programme and 159 pounds per kg for the 52-week one. Co-funded by Weight Watchers International under a Medical Research Council industrial collaboration award.
Heshka 2003 ran the two-year version against self-help across six US academic centres in 423 adults. Intention to treat weight loss was minus 4.3 against minus 1.3 kg at one year and minus 2.9 against minus 0.2 kg at two years, both p < 0.001, with 71 and 75 percent completing. The clause that gets dropped from summaries is in the same abstract: between-group differences in blood pressure, lipids, glucose and insulin were mainly non-significant by year two.
Rock 2010 tested the prepared-meal and incentivised counselling model in 442 overweight and obese women over two years. Weight loss at 24 months was 7.4 kg (7.9 percent) for the centre-based arm, 6.2 kg (6.8 percent) for the telephone-based arm and 2.0 kg (2.1 percent) for usual care, p < 0.001. Weight data were available at 24 months for 92.1 percent of the sample, which is unusually good retention for this literature and makes the estimate more trustworthy than most.
Truby 2006 compared four commercial programmes against each other over six months in a UK community sample recruited through a television series. All four produced significant loss of weight and body fat against control and the four did not differ significantly from each other. Average intention to treat weight loss was 5.9 kg and fat loss 4.4 kg. The low carbohydrate arm lost significantly faster in the first four weeks and was no better by the end.
Two trials ran the programme in people with impaired glucose control. In 225 adults with prediabetes, twelve months on the commercial programme produced 5.5 percent weight loss against 0.2 percent on a national diabetes education counselling programme, with greater improvements in HbA1c and HDL. In 563 adults with type 2 diabetes across 16 US centres, HbA1c changed by minus 0.32 against plus 0.16 percentage points, 24 against 14 percent reached HbA1c below 7.0 (p = 0.004), weight fell 4.0 against 1.9 percent, and 26 against 12 percent reduced their diabetes medications (p < 0.001).

What happened when people just ate it

The systematic reviews are the free-living picture, and their value is that they report the attrition alongside the effect. Gudzune 2015, which declares no funding source, pooled 45 studies including 39 randomised trials. At twelve months, participants on the largest group programme achieved at least 2.6 percent greater weight loss than control or education; the prepared-meal programme achieved at least 4.9 percent; a second prepared-meal programme achieved at least 3.8 percent at three months; the very low calorie medical programmes achieved at least 4.0 percent greater short-term loss than counselling with attenuation beyond six months where it was reported; a low carbohydrate commercial programme achieved 0.1 to 2.9 percent; and one meal replacement brand produced mixed results. The review's own limitations are the useful part: many trials were short, had high attrition and lacked blinding, and there was limited evidence to evaluate adherence or harms for any programme. The earlier review, Tsai 2005, is blunter still. Its conclusion was that with the exception of one trial the evidence supporting the major commercial and self-help programmes was suboptimal, that medically supervised very low calorie programmes produced 15 to 25 percent weight loss in people who completed treatment but came with high costs, high attrition and a high probability of regaining 50 percent or more of what was lost within one to two years, and that because many studies did not control for high attrition the reported results are probably a best-case scenario. Both reviews point the same way as the wider literature: in a trial comparing four popular diets directly, weight loss correlated with self-reported adherence at r = 0.60 and with which diet it was at r = 0.07.

Protein, and whether it confounds the result

None of these programmes is defined by a protein target and none of the trials reported protein intake or measured lean mass, so no lean mass figure can be quoted for any of them. That is a real gap rather than a technicality, because these are among the few weight loss interventions people stay on for a year or more, and because the number of people combining a commercial programme with a GLP-1 receptor agonist is now large. The protein section of this site carries the intakes that were measured and what each produced, and anyone running one of these programmes will have to supply that layer themselves.

The measured intakes behind the protein figures are on the protein page.

What reliably moves

Marker	Direction	From
Body weight at twelve months	Down, by roughly 2.6 to 4.9 percent more than control	Across 45 studies and 39 randomised trials, the group programme achieved at least 2.6 percent greater loss and the prepared-meal programme at least 4.9 percent, both against control or education.
Body weight at two years	Still better than comparator and shrinking	Minus 2.9 against minus 0.2 kg in the two-year self-help comparison, 7.4 kg against 2.0 kg in the prepared-meal trial, and still significant at two years in the dose trial. Nothing in this literature runs longer.
HbA1c in type 2 diabetes	Down	Minus 0.32 against plus 0.16 percentage points over twelve months in 563 adults, with 24 against 14 percent reaching HbA1c below 7.0 (p = 0.004).
Diabetes medication use	Down	26 against 12 percent of participants reduced their diabetes medications over twelve months (p < 0.001). This is the same kind of result the low carbohydrate diabetes trials produced, and it is the kind a primary endpoint often misses.
Blood pressure, lipids, glucose and insulin at two years	Mostly no difference against the comparator	From the two-year self-help comparison, where the weight difference persisted and the biological differences were mainly non-significant by year two. Reported here because it is routinely dropped.
Attrition	High, in every trial	39 and 46 percent not completing the twelve-month assessment in the primary care trial, 35 and 32 percent not assessed at one and two years in the dose trial. The exception is the prepared-meal trial, which retained 92.1 percent to 24 months.
Cost per kilogram lost	Measured, unusually	Over two years, 91 pounds per kg for a twelve-week referral and 159 pounds per kg for a 52-week one. Modelled over 25 years the twelve-week programme dominated brief intervention and the 52-week one came out at 2,394 pounds per quality-adjusted life-year.

Long term, and hard outcomes

Two years is the outer edge and the picture there is consistent: the weight advantage persists and shrinks, and the biochemical advantages mostly do not persist. No trial of a commercial programme has measured a cardiovascular event, a fracture or a death. The funding pattern has to be stated in both directions, because it is unusual. The two largest European trials were funded by the company whose programme was being tested, in both cases routed through UK Medical Research Council mechanisms, and both published findings that complicate the company's story: high attrition in one, and in the other an explicit cost per kilogram. The independent systematic review, which declares no funding source, reached a favourable conclusion about the same programme while naming short durations, high attrition and absent blinding as limitations. The earlier independent review reached a much less favourable one and described the published results as probably a best-case scenario. A reader who wants one sentence should take this one: the effect is real, it is in the range of 2 to 5 percent of body weight above doing nothing at a year, it is measured mostly in people who stayed in the trial, and it is the largest effect any self-directed dietary pattern on this site has demonstrated against an active comparator.

Citations

Human2011
Primary care referral to a commercial provider for weight loss treatment versus standard care: a randomised controlled trial
The Lancet
772 adults in Australia, Germany and the UK randomised to twelve months of guideline standard care or free commercial programme membership. Minus 5.06 against minus 2.25 kg by last observation carried forward, adjusted difference minus 2.77 kg. Completion 61 and 54 percent. Funded by Weight Watchers International through a grant to the UK Medical Research Council.
Human2017
Extended and standard duration weight-loss programme referrals for adults in primary care (WRAP): a randomised controlled trial
The Lancet
1,267 adults randomised 2:5:5 to brief advice, twelve weeks or 52 weeks of the programme. One-year weight change minus 3.26, minus 4.75 and minus 6.76 kg. Programme beat brief advice by minus 2.71 kg and 52 weeks beat twelve by minus 2.14 kg, both p < 0.0001, still significant at two years. Co-funded by Weight Watchers International.
Human2003
Weight loss with self-help compared with a structured commercial program: a randomized trial
JAMA
423 adults across six US academic centres, two years. Intention to treat weight loss minus 4.3 against minus 1.3 kg at one year and minus 2.9 against minus 0.2 kg at two years, both p < 0.001. Between-group differences in blood pressure, lipids, glucose and insulin were mainly non-significant by year two.
Human2010
Effect of a free prepared meal and incentivized weight loss program on weight loss and weight loss maintenance in obese and overweight women: a randomized controlled trial
JAMA
442 women, two years. Weight loss at 24 months 7.4 kg (7.9 percent) centre-based, 6.2 kg (6.8 percent) telephone-based and 2.0 kg (2.1 percent) usual care, p < 0.001. Weight data available for 92.1 percent at 24 months, the best retention in this literature.
Human2006
Randomised controlled trial of four commercial weight loss programmes in the UK: initial findings from the BBC diet trials
BMJ
Four commercial programmes over six months in a community sample. All produced significant weight and body fat loss against control and the four did not differ significantly from each other. Intention to treat average 5.9 kg weight and 4.4 kg fat. The low carbohydrate arm lost faster for four weeks and was no better by the end.
Human2016
Comparison of Commercial and Self-Initiated Weight Loss Programs in People With Prediabetes: A Randomized Control Trial
American Journal of Public Health
225 adults with prediabetes randomised to a commercial weight management programme or a national diabetes education counselling programme. Weight loss 5.5 against 0.8 percent at six months and 5.5 against 0.2 percent at twelve, both p < 0.001, with greater improvements in HbA1c and HDL cholesterol.
Human2016
Randomized controlled trial of a nationally available weight control program tailored for adults with type 2 diabetes
Obesity
563 adults with type 2 diabetes across 16 US centres, twelve months, commercial programme plus diabetes educator contact against standard care. HbA1c minus 0.32 against plus 0.16 percentage points, 24 against 14 percent below 7.0 (p = 0.004), weight minus 4.0 against minus 1.9 percent, and 26 against 12 percent reduced diabetes medications (p < 0.001). Follow-up 86 percent.
Review2015
Efficacy of commercial weight-loss programs: an updated systematic review
Annals of Internal Medicine
45 studies including 39 randomised trials, primary funding source declared as none. At twelve months the group programme achieved at least 2.6 percent and the prepared-meal programme at least 4.9 percent greater weight loss than control or education. Limitations named by the authors: many trials short, high attrition, no blinding, and limited evidence on adherence or harms.
Review2005
Systematic review: an evaluation of major commercial weight loss programs in the United States
Annals of Internal Medicine
The earlier and less favourable review. Concluded that with one exception the evidence was suboptimal. Medically supervised very low calorie programmes produced 15 to 25 percent loss in completers with high costs, high attrition and a high probability of regaining 50 percent or more within one to two years. Reported results described as probably a best-case scenario.
Review2014
Comparison of weight loss among named diet programs in overweight and obese adults: a meta-analysis
JAMA
48 randomised trials, 7,286 people, network meta-analysis. Weight loss differences between individual named diets were minimal. Behavioural support contributed 3.23 kg at six months and exercise 2.13 kg between six and twelve months. Conclusion: recommend any diet the patient will adhere to.
Human2005
Comparison of the Atkins, Ornish, Weight Watchers, and Zone diets for weight loss and heart disease risk reduction: a randomized trial
JAMA
160 adults, four popular diets, one year, completion 50 to 65 percent. Weight loss correlated with self-reported adherence at r = 0.60 (p < 0.001) and with diet type at r = 0.07 (p = 0.40). Each diet cut the LDL to HDL ratio by about 10 percent.

What people report

These are uncontrolled self-reports, not evidence. They are here because they tell you what to expect and what to watch for, which the trial literature does not. They cannot tell you whether anything works.

Accountability from the weekly weigh-in is the most commonly cited reason people say it works for them, and it is also the most commonly cited reason people say they dread it.
The simplified points or portion system is repeatedly described as the feature that made tracking sustainable, in contrast to counting calories directly.
Group meetings valued highly by some and avoided entirely by others, with the online-only members often reporting worse results, which the dose trial is consistent with but did not test.
Regain after cancelling, reported very widely, and matched by the review finding a high probability of regaining half or more after the very low calorie programmes.
No effect, reported by people who attended and did not follow the plan, which is what the adherence correlation of r = 0.60 against a diet type correlation of r = 0.07 describes.
Resentment at paying a subscription to be told to eat less, the most common reason given for stopping.
Reports of the points system encouraging low-calorie processed products over whole foods, which no trial measured.

Sources: r/WeightWatchers, r/loseit and long-running programme forums, plus the attrition and retention data inside the trials, which is the more informative half: 61 and 54 percent completing the twelve-month assessment in the primary care trial against 92.1 percent retained to 24 months in the prepared-meal trial. Uncontrolled self-report otherwise.

Who this is wrong for

Anyone taking insulin or a sulfonylurea who joins without telling their prescriber. Reducing diabetes medication was an outcome of the diabetes trial, at 26 against 12 percent of participants, and it happened under clinical supervision.
Anyone with a history of disordered eating. Group weigh-ins and a points score are a poor structural fit, and the largest systematic review of this literature found limited evidence to evaluate harms for any programme, which is an absence of data rather than a finding of safety.
Anyone reading a completers analysis as the expected result. In the same primary care trial, the completers estimate was minus 6.65 kg and the baseline-carried-forward estimate was minus 4.06 kg.
Anyone entering a medically supervised very low calorie programme without knowing the regain data. Those programmes produced 15 to 25 percent weight loss in completers alongside high costs, high attrition and a high probability of regaining 50 percent or more within one to two years.
Anyone expecting the specific programme to be the active ingredient. Four commercial programmes compared head to head over six months did not differ significantly from each other, and in a 48-trial network meta-analysis the differences between named diets were minimal while behavioural support accounted for 3.23 kg at six months.
Anyone for whom the subscription cost is the binding constraint and who would be choosing between it and food. The cost-effectiveness analysis is a health system calculation, not a household one.

Questions

Do commercial weight loss programmes actually work?: Against standard primary care, yes, and this is the strongest head to head evidence any consumer diet product on this site has. Referral to a commercial programme produced minus 5.06 kg against minus 2.25 kg on standard care at twelve months, and a 52-week referral produced minus 6.76 kg against minus 3.26 kg on brief advice. An independent systematic review of 45 studies put the twelve-month advantage at at least 2.6 percent of body weight for the group programme and at least 4.9 percent for the prepared-meal one.
Who paid for those trials?: Mostly the company being tested. The two largest European trials were funded by Weight Watchers International, in both cases through UK Medical Research Council mechanisms. That is disclosed in the papers and it belongs in any honest reading of them. It also cuts both ways: the industry-funded trials published high attrition and a cost per kilogram, and the systematic review that declares no funding source reached a favourable conclusion about the same programme.
Does the weight stay off?: Partly, for as long as anyone has looked, which is two years. The two-year comparison against self-help finished at minus 2.9 against minus 0.2 kg, down from minus 4.3 at one year. The prepared-meal trial finished at 7.4 kg down at 24 months. The very low calorie medical programmes are the exception in both directions: 15 to 25 percent loss in completers, and a high probability of regaining half or more within one to two years.
Is one programme better than another?: Not on the direct comparison. Four commercial programmes run head to head for six months all beat control and did not differ significantly from each other, averaging 5.9 kg lost. In a network meta-analysis of 48 trials the differences between named diets were minimal while behavioural support accounted for 3.23 kg at six months. The structure appears to be the active ingredient, not the brand.
What about diabetes?: Two randomised trials tested it. In prediabetes, twelve months produced 5.5 percent weight loss against 0.2 percent on a national counselling programme, with better HbA1c and HDL. In type 2 diabetes, HbA1c moved minus 0.32 against plus 0.16 percentage points, 24 against 14 percent reached HbA1c below 7.0, and 26 against 12 percent reduced their diabetes medications. That last figure is why anyone on insulin or a sulfonylurea should tell their prescriber before joining.